Literature DB >> 31015231

Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology.

Kalevi Kairemo1, Wei-Lien Wang2, Vivek Subbiah3.   

Abstract

Malignant transformation of giant cell tumour of the bone is extremely rare. In addition, bone transformation in giant cell tumour may occur in different phases. With conventional X-rays, CT scans or MRIs, it may be challenging to distinguish among different phases of bone transformation, normal bone, soft tissue disease and bone disease (benign vs malignant lesions) and changes in multiple organs such as lung, liver and lymph nodes unless every lesion is biopsied, which is not practical. Molecular imaging with different isotopes (Tc-99m phosphonate, 2-deoxy-2-(18F)fluoro-d-glucose and sodium fluoride-18) may help to better characterise the disease. We hypothesised that molecular imaging could offer qualitative and quantitative characterisation of all stages of bone formation, destruction, reactivity or neoplasia in a patient with giant cell tumour of the bone, and we present the first case of molecular imaging where bone formation was seen in multiple soft tissues, such as lungs, muscles, lymph nodes and liver. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; carcinogenesis; radiology; screening (oncology)

Mesh:

Substances:

Year:  2019        PMID: 31015231      PMCID: PMC6510129          DOI: 10.1136/bcr-2016-218839

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation.

Authors:  Y Oda; A Sakamoto; T Saito; S Matsuda; K Tanaka; Y Iwamoto; M Tsuneyoshi
Journal:  Histopathology       Date:  2001-12       Impact factor: 5.087

Review 2.  FDG PET/CT of primary bone tumors.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell
Journal:  AJR Am J Roentgenol       Date:  2014-06       Impact factor: 3.959

3.  Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Authors:  Vivek Subbiah; Pete M Anderson; Kalevi Kairemo; Kenneth Hess; Winston W Huh; Vinod Ravi; Najat C Daw; Neeta Somaiah; Joseph A Ludwig; Robert S Benjamin; Sant Chawla; David S Hong; Funda Meric-Bernstam; Gregory Ravizzini; Eugenie Kleinerman; Homer Macapinlac; Eric Rohren
Journal:  Clin Cancer Res       Date:  2019-02-07       Impact factor: 12.531

4.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Authors:  David Thomas; Robert Henshaw; Keith Skubitz; Sant Chawla; Arthur Staddon; Jean-Yves Blay; Martine Roudier; Judy Smith; Zhishen Ye; Winnie Sohn; Roger Dansey; Susie Jun
Journal:  Lancet Oncol       Date:  2010-02-10       Impact factor: 41.316

5.  Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.

Authors:  Andrew Park; Cara A Cipriano; Kirk Hill; Michael Kyriakos; Douglas J McDonald
Journal:  JBJS Case Connect       Date:  2016 Jul-Sep

6.  Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Authors:  Daniel G Branstetter; Scott D Nelson; J Carlos Manivel; Jean-Yves Blay; Sant Chawla; David M Thomas; Susie Jun; Ira Jacobs
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

7.  Malignant transformation of a giant cell tumor 25 years after initial treatment.

Authors:  Y Mori; H Tsuchiya; M Karita; A Nonomura; T Nojima; K Tomita
Journal:  Clin Orthop Relat Res       Date:  2000-12       Impact factor: 4.176

Review 8.  A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.

Authors:  Luis A Aponte-Tinao; Nicolas S Piuzzi; Pablo Roitman; German L Farfalli
Journal:  Clin Orthop Relat Res       Date:  2015-03-11       Impact factor: 4.176

9.  Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.

Authors:  T Ueda; H Morioka; Y Nishida; S Kakunaga; H Tsuchiya; Y Matsumoto; Y Asami; T Inoue; T Yoneda
Journal:  Ann Oncol       Date:  2015-07-23       Impact factor: 32.976

10.  Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.

Authors:  Kalevi Kairemo; Eric M Rohren; Pete M Anderson; Gregory Ravizzini; Arvind Rao; Homer A Macapinlac; Vivek Subbiah
Journal:  ESMO Open       Date:  2019-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.